The
study analysed that the Amyotrophic
lateral sclerosis pipeline comprises of 69 drug candidates, of
which one drug candidate is in Phase III stage, 16 drug candidates are in Phase
II stage, nine drug candidates are in Phase I stage, 32 drug candidates are in
Pre-Clinical stage, five candidates are inactive and six drug candidates are in
discontinued stage. Amyotrophic lateral sclerosis is a neurodegenerative
disorder in brain and spinal cord, the progression of the disease can further
lead to muscles getting enough nourishments, which can further cause atrophy of
the muscles. Amyotrophic Lateral Sclerosis occurs mostly in the lateral region of
the body, in which spinal cord reflexes are too intense. This can also lead to
scarring and hardening of the muscles into that region. Various new therapies
and advanced technologies are driving the growth of Amyotrophic lateral
sclerosis pipeline.
Explore Report Overview at: https://www.psmarketresearch.com/market-analysis/amyotrophic-lateral-sclerosis-pipeline-analysis
Insights on
pipeline segments
As
per the findings of the research, around 31.0% of drug candidates for the
treatment of amyotrophic lateral sclerosis pipeline are being developed to be
administered by oral route, 4.0% by intravenous route, 48.0% are not disclosed
and 17.0% are to be administered by other routes which includes subcutaneous,
intraperitoneal, sublingual, inhalation and intramuscular.
Major companies collaborate for the development
of Amyotrophic Lateral Sclerosis Pipeline
The
research also found that various companies have collaborated for the
development of amyotrophic lateral sclerosis pipeline. In March 2013, Dainippon
Sumitomo Pharma Co., Ltd. signed a research, development and commercial
licensing agreement with Edison Pharmaceuticals, Inc. for EPI-743 and EPI-589
in Japan. Dainippon Sumitomo Pharma Co., Ltd. received exclusive research,
development and commercial rights in Japan for EPI-743 and EPI-589. Edison
Pharmaceuticals, Inc. received $35.0 million in an upfront payment and $15.0
million as research and development support fee. In addition, Edison
Pharmaceuticals, Inc. also received $10.0 to $35.0 million in milestone
payments per indication associated with successful development. After the launch,
Edison Pharmaceuticals, Inc. received royalties based on sales amounts and up
to $460.0 million in milestone payments in accordance with sales goals.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/amyotrophic-lateral-sclerosis-pipeline-analysis/report-sample
Many companies are
developing Amyotrophic lateral sclerosis drug candidates in different phases.
Cytokinetics, Inc., AB Science, F. Hoffman La-Roche AG, FlexPharma, Inc., Orion
Corporation, Omeros Corporation, Genervon Biopharmaceuticals, LLC, Edison
Pharmaceuticals, Inc., BrainStorm Cell Therapeutics, Inc. and various other
companies have their Amyotrophic lateral sclerosis drug candidates in different
stages of development. Cytokinetics, Inc. has drug candidate in Phase III
clinical stage.
No comments:
Post a Comment